Related | Immune Thrombocytopenia (ITP) in Children - Pediatric - Inpatient/Ambulatory/Emergency Department
1
Immune Thrombocytopenia (ITP) in Children -
Pediatric - Inpatient/Ambulatory/Emergency
Department
External Clinical Practice Guideline
Endorsement
Note: Active Table of Contents – Click each header below to jump to the section of interest
Table of Contents
INTRODUCTION .................................................................................................................................3
SCOPE ................................................................................................................................................3
RECOMMENDATIONS .........................................................................................................................4
TABLE 1. SUMMARY OF ASH GUIDELINE RECOMMENDATIONS FOR THE MANAGEMENT OF ITP1,8 ........5
TABLE 2. SUMMARY OF KEY POINTS FOR 1ST AND 2ND LINE MEDICATIONS FOR ITP IN CHILDREN ..........7
METHODOLOGY .................................................................................................................................8
APPENDIX A. MANAGEMENT OF IMMUNE THROMBOCYTOPENIA IN CHILDREN ................................. 11
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
2
Content Expert(s):
Christina Amend, MD – Pediatric Hematology/Oncology
Email Address: CAmend@pediatrics.wisc.edu
Workgroup Members:
Luke Addesso, MD – General Pediatrics
Justin Graff, PharmD - Pharmacy
Cathy Lee-Miller, MD - Pediatric Hematology/Oncology
Mary Mably, RPh – Pharmacy
Sarah Mc Dermott, DO, MBS - Pediatric Hematology/Oncology
Daniel Sklansky, MD – Pediatric Hospitalist
Reviewer(s):
Allie Hurst, MD – Emergency Medicine
Anne Marsh, MD - Pediatric Hematology/Oncology
Contact for Changes:
Center for Clinical Knowledge Management (CCKM)
Email Address: CCKM@uwhealth.org
Guideline Author:
Lee Skrupky, PharmD – Center for Clinical Knowledge Management
Committee Approval(s):
Clinical Knowledge Management (CKM) Council (03/28/24)
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
3
Introduction
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder in which a low platelet
count (<100 x 109/L) results from destruction of existing platelets and impaired production of
new platelets. ITP is the most common cause of thrombocytopenia in children, with an
estimated incidence of ~2-10 cases per 100,000 children annually (peak incidence between
ages 2-5 years)1-5. A typical presentation involves an otherwise healthy child with petechiae,
bruising, and/or mild mucosal bleeding. In most pediatric cases, ITP is mild and resolution often
occurs without intervention; when treatment is required, approximately three-quarters will
respond to 1st line therapies. However, severe bleeding does occur rarely (≤1%) and is the
primary concern given the risk of severe morbidity and mortality1-5.
ITP can be primary or secondary in nature; primary ITP is when there are no other apparent
causes of thrombocytopenia and secondary ITP is when there is an identifiable associated
condition1,6,7. Primary ITP makes up the majority (~80%) of cases1,6,7 and is the focus of this
guideline. ITP is also categorized based on the duration of thrombocytopenia as follows1:
• Newly diagnosed ITP (<3 months duration)
• Persistent ITP (3-12 months duration)
• Chronic ITP (>12 months duration)
In 2019, the American Society of Hematology (ASH) published an update to their 2011 clinical
practice guideline8 for the management of ITP in adults and children. This update1 addressed 21
questions based on a review and appraisal of the primary literature through 2017;
recommendations 10-21 and 2 good practice statements are specific to the management of
children with newly diagnosed ITP. These guidelines are intended to address the management
of patients with non-life-threatening bleeding and are noted to exclude emergency management
and pregnancy. In this endorsement guideline, we outline recommendations for the
management of children with ITP who do not have severe bleeding requiring emergency care.
Scope
Intended User(s): Physicians, Advanced Practice Providers, Nurses, Pharmacists
Objective(s): To provide standardized, evidence-based guidelines for the assessment and
management of primary ITP in children
Target Population: Children (age 1-17 yrs) with suspected primary ITP
Clinical Questions Considered:
• When should children with ITP be admitted to the hospital for treatment?
• What treatments are recommended for children with newly diagnosed ITP?
• What treatments are recommended for children with ITP who do not respond to first-line
therapies?
Definitions1
Thrombocytopenia: Platelet count <100 x 109/L
Newly diagnosed ITP: <3 months duration
Persistent ITP: 3-12 months duration
Chronic ITP: >12 months duration
Minor bleeding: bleeding that involves only cutaneous manifestations (i.e. bruising, petechiae)
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
4
Non-life-threatening mucosal bleeding: Bleeding that involves only mucosal surfaces and does
not require emergent transfusion or intervention (i.e. epistaxis, gum bleeding, menorrhagia)
Remission: Platelet count >100 x 109/L at 12 months
Recommendations
Diagnosis
As there is no single test that identifies ITP, a diagnosis of primary ITP is established on a
clinical basis through a patient history, physical examination, complete blood count and
peripheral smear1,3-6,8. A diagnosis of ITP is made when these examinations yield:
• isolated thrombocytopenia (<100 x 109/L) on the CBC
• no abnormal findings on peripheral smear
• an absence of findings that would raise concern for other causes of thrombocytopenia
When patients meet the typical criteria outlined above, there is no need to investigate further for
potential underlying autoimmune or bone marrow conditions. Therefore, additional tests such as
a bone marrow biopsy, antinuclear antibody testing, or immunoglobulin testing are not routinely
recommended to establish the diagnosis1,3-6,8 (see Table below for ASH recommendations against
such testing in specific scenarios). If atypical features are present or there is concern for other
conditions associated with thrombocytopenia (i.e. systemic illness, infection, malignancy,
autoimmune illness, medications), consider hematology consultation and additional referrals to
help guide further work-up (UW Health Best Practice Statement).
Treatment
UW Health endorses the recommendations pertaining to children (#10-21) within the American
Society of Hematology (ASH) 2019 guidelines1 for immune thrombocytopenia and also the
carried over recommendations from 2011 ASH guideline8 that were not changed/updated in
2019. The endorsed ASH Guideline recommendations for the management of children with ITP
are summarized in Table 1.
Appendix A includes an algorithm that is based on these recommendations, outlining our
internal guidance for the management of pediatric ITP. Finally, Table 2 provides a summary of
key details for each of the first- and second-line medical therapies for ITP.
The decision on whether to treat is not based on platelet count alone but instead takes into
consideration the bleeding risk and health-related quality of life (HRQoL) of the patient1,3-6,9.
HRQoL is not explicitly defined in the ASH Guideline, but considerations include not only
physical health but also mental and social domains; examples from these latter domains may
include restrictions on activities, anxiety due to the risk of bleeding, depression, fatigue, and the
burden of treatment and monitoring. The overall treatment goals are to keep children safe,
resolve bleeding and any symptoms, and minimize lab draws. The frequency of laboratory
monitoring will vary according to patient specific considerations including clinical stability, the
presence or absence of symptoms (bleeding, fatigue, diminished QOL), platelet count value and
trend, and any treatment being used10. Until remission is achieved, labs (i.e. CBC) should
generally be considered every 1-4 weeks; more frequent monitoring (i.e. weekly) should be
considered when there are symptoms requiring treatment and/or more severe
thrombocytopenia, whereas less frequent monitoring (i.e. monthly) is appropriate if the child is
asymptomatic and has only moderate thrombocytopenia.
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
5
Platelet transfusions are indicated only in the presence of severe bleeding and life-threatening
situations, and are not used to attempt to reach an arbitrary platelet count value3,4,11. While
platelets are < 50 x 109/L, children should be on activity restrictions (when feasible) to avoid
injury and medications that might adversely affect platelet function and increase bleeding risk
(i.e. NSAIDs, aspirin) should be avoided4,10.
Table 1. Summary of ASH Guideline Recommendations for the Management of ITP1,8
Topic Recommendations Level
Diagnostic (Carried forward from 2011 ASH Guideline)
Diagnosis of ITP We recommend:
• Bone marrow examination is unnecessary in children and
adolescents with the typical features of ITP
• Bone marrow examination is not necessary in children who
fail IVIG therapy
Grade 1B
We suggest:
• Bone marrow examination is also not necessary in similar
patients prior to initiation of treatment with corticosteroids or
before splenectomy
• Testing for antinuclear antibodies is not necessary in the
evaluation of children and adolescents with suspected ITP
Grade 2C
Testing in
treatment
nonresponders
We recommend against routine testing for H. pylori in
children with chronic ITP
Grade 1B
Management of MMR-associated ITP (Carried forward from 2011 ASH Guideline)
MMR vaccine -
associated ITP
considerations
Children with a history of ITP who are unimmunized receive
their scheduled first MMR vaccine
Grade 1B
In children with either nonvaccine or vaccine-related ITP
who have already received their first dose of MMR vaccine,
vaccine titers can be checked; if the child displays full
immunity (90% to 95% of children), then no further MMR
vaccine should be given; if the child does not have adequate
immunity, then the child should be reimmunized with MMR
vaccine at the recommended age.
Grade 1B
Treatment Setting (From ASH 2019 Guideline)
Outpatient vs.
Inpatient
Management
In children with newly diagnosed ITP and a platelet count of
<20 x 109/L who have no or mild bleeding (skin
manifestations) only, the ASH guideline panel suggests
against admission to the hospital rather than outpatient
treatment
Conditional,
Very low certainty
of evidence
In children with newly diagnosed ITP and a platelet count of
≥20 x 109/L who have no or mild bleeding (skin
manifestations) only, the ASH guideline panel suggests
against admission to the hospital rather than outpatient
treatment
Conditional,
Very low certainty
of evidence
The referring physician should ensure that the patient
has follow-up with a hematologist within 24 to 72 hours of
diagnosis.
Good practice
statement
Medical Management (From ASH 2019 Guideline)
Treatment vs.
Observation
In children with newly diagnosed ITP who have no or minor
bleeding, the ASH guideline panel suggests observation
rather than corticosteroids
Conditional,
Very low certainty
of evidence
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
6
In children with newly diagnosed ITP who have no or minor
bleeding, the ASH guideline panel recommends observation
rather than IVIG
Strong,
Moderate
certainty of
evidence
In children with newly diagnosed ITP who have no or minor
bleeding, the ASH guideline panel recommends observation
rather than anti-D immunoglobulin
Strong,
Moderate
certainty of
evidence
Treatment of
children with non–
life-threatening
mucosal bleeding
and/or diminished
HRQoL
In children with newly diagnosed ITP who have non–life-
threatening mucosal bleeding and/or diminished HRQoL, the
ASH guideline panel suggests corticosteroids rather than
anti-D immunoglobulin
Conditional,
Low certainty of
evidence
In children with newly diagnosed ITP who have non–life-
threatening mucosal bleeding and/or diminished HRQoL, the
ASH guideline panel suggests corticosteroids rather than
IVIG
Conditional,
Low certainty of
evidence
In children with newly diagnosed ITP who have non–life-
threatening mucosal bleeding and/or diminished HRQoL
[and whom cannot tolerate/receive corticosteroids OR
previously failed corticosteroids], the ASH guideline panel
suggests either anti-D immunoglobulin or IVIG
Conditional,
Low certainty of
evidence
Corticosteroid
duration and type
In children with newly diagnosed ITP who have non–life-
threatening bleeding and/or diminished HRQoL, the ASH
guideline panel recommends against courses of
corticosteroids longer than 7 days rather than courses 7
days or shorter
Strong,
Very low certainty
of evidence
In children with newly diagnosed ITP who have non–life-
threatening mucosal bleeding and/or diminished HRQoL, the
ASH guideline panel suggests prednisone (2-4 mg/kg per
day; maximum, 120 mg daily, for 5-7 days) rather than
dexamethasone (0.6 mg/kg per day; maximum, 40 mg per
day for 4 days)
Conditional,
Very low certainty
of evidence
Management of
children with ITP
who do not have a
response to 1st line
treatment
In children with ITP who have non–life-threatening mucosal
bleeding and/or diminished HRQoL and do not respond to
first-line treatment, the ASH guideline panel suggests the
use of TPO-RAs rather than rituximab
Conditional,
Very low certainty
of evidence
In children with ITP who have non–life-threatening mucosal
bleeding and/or diminished HRQoL and do not respond to
first-line treatment, the ASH guideline panel suggests TPO-
RAs rather than splenectomy
Conditional,
Very low certainty
of evidence
In children with ITP who have non–life-threatening mucosal
bleeding and/or diminished HRQoL and do not respond to
first-line treatment, the ASH guideline panel suggests
rituximab rather than splenectomy
Conditional,
Very low certainty
of evidence
The treating physician should ensure that the patient has
appropriate immunizations prior to splenectomy and that
they receive counseling regarding antibiotic prophylaxis
following splenectomy. The treating physician should
educate the patient on prompt recognition and management
of fever and refer to current recommendations on pre- and
post-splenectomy care.
Good practice
statement
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
7
Table 2. Summary of Key Points for 1st and 2nd Line Medications for ITP in Children
* Medication information obtained from Lexi-comp® drug monographs except where cited otherwise. Clinical Pearls are based on expert opinions from UW Health subject matter experts.
Drug Dosing Information
(Assumes normal organ function)
Contraindications,
Warnings /
Precautions, Drug
Interactions
Adverse Effects
(Select common and significant
toxicities reported here; refer to Lexi-
comp® for complete list)
Clinical Pearls
(Pearls are based on expert opinions from internal subject matter
experts regarding drug selection, patient monitoring)
First-line Acute Therapies
Prednisone 2-4 mg/kg/day orally (max 120 mg daily) in
3-4 divided doses, for 5-7 days
Review in Lexi-comp® Gastritis
Insomnia
Mood/behavior changes
Increased appetite, weight gain
Hypertension
Hyperglycemia
Time to response: 2-7 days
Prolonged durations are not recommended and tapers are not
needed with short durations.
Prednisone is preferred over dexamethasone.
IVIG 0.8–1 g/kg IV for 1-2 days3,4,6,11
Alternative Dosing: 400 mg/kg IV for 5 days
See UW Health IVIG Guideline for further
details regarding pre-medication, infusion
rates, monitoring.
Review in Lexi-comp® Headache
Fever, chills
Nausea, vomiting
Infusion reactions
Hypersensitivity reaction
Rare (<1%) possibilities include:
Thrombosis, renal failure, hemolytic
anemia, and aseptic meningitis
Time to response: 1-2 days (usually within 24 hrs)
May be preferred when a rapid rise in platelet count is needed and
can be used in combination with corticosteroids for more severe
cases
Anti-D Ig
50–75 mcg/kg over slow IV push (3-5 min) Review in Lexi-comp® Fever, chills
Headache
Infusion reactions
Severe intravascular hemolysis is a
rare possibility –monitor for 8h post-
infusion
Time to response: 1-2 days
May be considered as an alternative to IVIG in select patients;
Patient must be Rh-positive, DAT-negative, and not splenectomized
Second-line Therapies
Eltrombopag
(TPO receptor
agonist)
1–6 y: 25 mg/day orally
>6-yrs: 50 mg/day orally (Reduce initial
dose to 25 mg once daily if East/Southeast
Asian ancestry (e.g., Chinese, Japanese,
Korean, Taiwanese)
Max dose 75 mg/day
Take without a meal or with a meal low in
calcium (=50 mg) and ≥ 2 hrs before and 4
hrs after Ca-containing foods or
medications/supplements containing Ca,
Fe, Al, Mg, Se, or Zn.
Review in Lexi-comp® Abdominal pain
Diarrhea
Headache
Arthralgia, myalgia
Abnormal hepatic function tests
Re-evaluate platelet count in 2 weeks after initiation and use lowest
dose that achieves platelet count goal (i.e. >50k) to reduce bleeding.
• Eltrombopag: If below goal, increase in 12.5mg-25mg
increments bi-weekly to max dose
• Romiplostim: If below goal, increase by 1 mcg/kg weekly to
max dose
Discontinue if platelet count does not respond to a level that avoids
clinically important bleeding after 4 weeks at the max daily dose.
Thrombocytopenia is likely to recur following treatment cessation,
but some (10-30%) may experience sustained response after taper
and discontinuation
Romiplostim
(TPO receptor
agonist)
Initial 1 mcg/kg subcutaneously once
weekly (Dosing range 1-10 mcg/kg weekly)
Review in Lexi-comp® Rash
Abdominal pain
Diarrhea
Headache
Arthralgia, myalgia
Rituximab 375 mg/m2 IV infusion weekly × 4 doses4,12 Review in Lexi-comp® Headache
Fever, Chills
Urticaria
Serum sickness
Progressive multifocal
leukoencephalopathy (Rare)
Time to response: 3 weeks
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
8
Disclaimer
Clinical practice guidelines assist clinicians by providing a framework for the evaluation and
treatment of patients. This guideline outlines the preferred approach for most patients. It is not
intended to replace a clinician’s judgment or to establish a protocol for all patients. It is
understood that some patients will not fit the clinical condition contemplated by a guideline and
that a guideline will rarely establish the only appropriate approach to a problem.
Conflicts of Interest
All guideline workgroup members are expected to follow institutional policies and procedures
around conflicts of interest. Actions in which a guideline member discloses a conflict of interest
relevant to the guideline topic may include, but is not limited to, abstaining from voting, dismissal
during comment and voting period, or recusal from requesting and/or participation in the
decision-making process.
Methodology
Development Process
Each guideline is reviewed and updated approximately every 3-5 years, but will vary in
consideration of the primary literature and relevant practice changes. All guidelines are
developed using the guiding principles, standard processes, and styling outlined in the UW
Health Clinical Practice Guideline Resource Guide. This includes expectations for workgroup
composition and recruitment strategies, disclosure and management of conflict of interest for
participating workgroup members, literature review techniques, evidence grading resources,
required approval bodies, and suggestions for communication and implementation.
Methods Used to Formulate the Recommendations:
Following a review and discussion of the literature, including the available national guidelines,
the workgroup members agreed to adopt recommendations pertaining to children developed by
American Society of Hematology (ASH)1,8. All recommendations endorsed or developed by the
guideline workgroup were reviewed and approved by other stakeholders or committees (as
appropriate). As the ASH ITP Guideline1,8 is considered to represent the gold standard for
guideline-directed therapy for pediatric ITP by UW Health internal experts, a formal AGREE II
guideline appraisal was not completed.
Methodology of the ASH 2019 Guideline1 for Immune Thrombocytopenia included an update to
their systematic review and appraisal of the evidence (up to May, 2017). The guideline panel (8
adult experts, 5 pediatric experts, 2 methodologists with expertise in ITP, and 2 patient
representatives) utilized the GRADE approach to conducting the evidence review and
developing recommendations. Following the GRADE approach, the ASH guidelines provide
evidence ratings for each of their recommendations in 4 potential categories: High, Moderate,
Low, and Very low certainty of evidence. Recommendations are categorized as either “Strong”
or “Conditional”1. UW Health-developed guidelines also employ the GRADE approach, and our
current corresponding definitions for these categories are outlined below. Table 4 of the ASH
2019 guideline provides the intended interpretations of their recommendation labels for the
different intended audiences including patients, clinicians, policy-makers, and researchers.
The ASH 2011 Guideline for Immune Thrombocytopenia utilized the following definitions for
assigning a strength of recommendation and evidence rating:
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
9
Strength of Recommendation
1 Indicates a high degree of confidence that the desirable outcomes of an
intervention exceed the undesirable effects (or vice versa) in most patient
populations.
2 Indicates a lower degree of confidence that the desirable outcomes
outweigh undesirable outcomes (or vice versa).
Quality of Evidence Ratings
A The recommendation is supported by consistent evidence from randomized
controlled trials (RCTs) or exceptionally strong observational studies
B The recommendation is supported by RCTs with important limitations or
strong evidence from observational studies
C The recommendation is derived from RCTs with serious flaws, weaker
observational studies, or indirect evidence
GRADE Methodology adapted by UW Health
Rating Scheme for the Strength of the Evidence/Recommendations:
GRADE Ranking of Evidence
High We are confident that the effect in the study reflects the actual effect.
Moderate
We are quite confident that the effect in the study is close to the true effect, but it is
also possible it is substantially different.
Low The true effect may differ significantly from the estimate.
Very Low The true effect is likely to be substantially different from the estimated effect.
Very Low -
Internal
Expert
Opinion
The true effect is likely to be substantially different from the estimated effect.
This category of recommendation for or against a specific intervention is derived
strictly from the expert opinions of UW Health healthcare professionals with experience
in the relevant specialty(ies). This is used in the absence of published evidence or
external opinion addressing the specific intervention.
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
10
GRADE Ratings for Recommendations For or Against Practice
Strong (S)
Generally should be performed (i.e., the net benefit of the treatment is clear,
patient values and circumstances are unlikely to affect the decision.)
Conditional (C)
May be reasonable to perform (i.e., may be conditional upon patient values and
preferences, the resources available, or the setting in which the intervention will
be implemented.)
Good Practice
Statement
Generally, should be performed (i.e., the expected benefit of the treatment is
substantial, expected costs or risk are minimal, and patient values and
circumstances are unlikely to affect the decision.)
This classification is used for recommendations that guideline members feel are
important and for which there is uniform support, but for which evidence directly
assessing the specific intervention (or practice) is not available and is highly
unlikely to ever be studied (because it may not be warranted or feasible). Such
recommendations may have strong indirect evidence of support
Collateral Tools & Resources
The following collateral tools and resources support staff execution and performance of the
evidence-based guideline recommendations in everyday clinical practice.
Metrics
% of ITP patients without bleeding or minor bleeding only undergoing period of observation vs. treatment
% of children with ITP treated in ambulatory setting
% of children with ITP receiving preferred 1st-line therapies
Patient Resources
Immune Thrombocytopenic Purpura (IRP) [HF 4787]
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
11
Appendix A. Management of Immune Thrombocytopenia in Children
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024
12
References
1. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019
guidelines for immune thrombocytopenia. Blood Adv. Dec 10 2019;3(23):3829-3866.
doi:10.1182/bloodadvances.2019000966
2. Neunert C, Heitink-Polle KMJ, Lambert MP. A proposal for new definition (s) and
management approach to paediatric refractory ITP: Reflections from the Intercontinental
ITP Study Group. Br J Haematol. Oct 2023;203(1):17-22. doi:10.1111/bjh.19072
3. Russo G, Parodi E, Farruggia P, et al. Recommendations for the management of acute
immune thrombocytopenia in children. A Consensus Conference from the Italian
Association of Pediatric Hematology and Oncology. Blood Transfus. Jul 27
2023;doi:10.2450/BloodTransfus.501
4. Singh G, Bansal D, Wright NAM. Immune Thrombocytopenia in Children: Consensus
and Controversies. Indian J Pediatr. Feb 2020;87(2):150-157. doi:10.1007/s12098-019-
03155-4
5. Verissimo V, Carter T, Wright H, et al. Australian and New Zealand consensus guideline
for paediatric newly diagnosed immune thrombocytopaenia endorsed by Australian New
Zealand Children's Haematology and Oncology Group. J Paediatr Child Health. May
2023;59(5):711-717. doi:10.1111/jpc.16395
6. Gafter-Gvili A. Current approaches for the diagnosis and management of immune
thrombocytopenia. Eur J Intern Med. Feb 2023;108:18-24.
doi:10.1016/j.ejim.2022.11.022
7. Grace RF, Lambert MP. An update on pediatric ITP: differentiating primary ITP, IPD, and
PID. Blood. Aug 11 2022;140(6):542-555. doi:10.1182/blood.2020006480
8. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011
evidence-based practice guideline for immune thrombocytopenia. Blood. Apr 21
2011;117(16):4190-207. doi:10.1182/blood-2010-08-302984
9. Kochhar M, Neunert C. Immune thrombocytopenia: A review of upfront treatment
strategies. Blood Rev. Sep 2021;49:100822. doi:10.1016/j.blre.2021.100822
10. Friedman JN, Beck CE. Diagnosis and management of typical, newly diagnosed primary
immune thrombocytopenia (ITP) of childhood. Paediatr Child Health. Feb 2019;24(1):54-
55. doi:10.1093/pch/pxy197
11. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the
investigation and management of primary immune thrombocytopenia. Blood Adv. Nov 26
2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812
12. Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with immune
thrombocytopenia: a systematic review. PLoS One. 2012;7(5):e36698.
doi:10.1371/journal.pone.0036698
Effective 3/28/2024. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2024 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 04/2024